Navigation Links
Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
Date:3/28/2008

SAN DIEGO, March 28 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced the company's licensee, AnGes MG, Inc., reported submission on March 27, 2008, of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare for its angiogenesis product candidate, Collategene, for treatment of critical limb ischemia. The treatment uses Vical technology to deliver a gene encoding hepatocyte growth factor (HGF), a human protein that causes growth of blood vessels in areas of restricted blood flow.

"The Japanese NDA filing positions Collategene to be the first product based on our DNA delivery technology with the potential to be approved for human use," said Vijay B. Samant, President and Chief Executive Officer of Vical. "In the United States, where it is estimated that more than 10 million people have peripheral arterial disease (PAD), AnGes already has completed two Phase 2 clinical trials of Collategene in PAD patients. This product candidate offers a novel approach to addressing an important, unserved medical need in the Japanese market, and has the potential to expand into the much larger markets worldwide. This NDA filing by AnGes is an important milestone in advancing nonviral gene therapy toward regulatory and commercial acceptance."

The NDA submission follows positive results announced in June 2007 following interim analysis of data from the first 41 subjects to complete a Phase 3 trial of Collategene. Based on the findings that the primary efficacy endpoint in the trial had been achieved with statistical significance and that there were no major safety concerns related to treatment, an Independent Data Monitoring Committee recommended stopping the trial early to prevent potential e
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vical to Present at Cowen and Company Health Care Conference
2. Vical to Present at BIO and BVGH Global Health Partnering Event
3. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
4. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
5. New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
6. Vical Launches Redesigned Website
7. Vical Presentation at Military Pandemic Influenza Workshop
8. Amedica Receives FDA 510(k) Clearance for Valeo(TM) Cervical Plate
9. Vical to Present at Investor Conferences
10. Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening
11. Vical Announces News Release and Conference Call Schedule for Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... November 20, 2014 The November 2014 ... as an open access journal featuring the following articles:, ... proteins to preserve photoresponsiveness in the retina , ... in situ hybridization using chromogenic substrates in zebrafish , ... RNA, and protein electrophoresis , Nuclear LC3-positive ...
(Date:11/21/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on the ... information, like its definition, classification, application, and industry ... report covers the international market analysis, including China’s ... the US, Europe, Asia, China, Japan etc. regions) ...
(Date:11/21/2014)... VANCOUVER , Nov. 20, 2014 /CNW/ - ... pleased to announce that it has closed a ... special warrants for approximately C$3.7 million.  Cormark Securities ... agents in the Brokered Offering for a syndicate ... and PI Financial Corp. (collectively the "Agents"). Concurrently ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood ... sponsor of the 10th Annual World Stem Cell Summit, the ... stakeholders. The 2014 World Stem Cell Summit will be held ... Antonio, Texas . The World ... development of lifesaving cures and therapies, convening the most prominent ...
Breaking Biology Technology:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3
... of,streamers this morning, the most famous mouse in the ... Hospital from Walt Disney,World and Disney Worldwide Outreach. With ... hospital, The Walt Disney Company and Florida Children,s,Hospital revealed ... for,the "Children,s Hospital of the Future." While The ...
... KONG, Sept. 19 /Xinhua-PRNewswire/ -- Shanghai Century (Amex:,SHA), ... Sichuan,Kelun Pharmaceutical Co., Ltd (Kelun), China,s largest producer ... with,unaudited financial highlights with respect to the consolidated ... variable interest entity,(Kelun Group) for the first half ...
... Commercialization and Supply Agreement, Company to Host Conference Call at 12:30 p.m. ... ... 2007, LEXINGTON, Mass., Sept. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... acquisition of Esprit Pharma, has obtained the,United States rights to SANCTURA(R) and ...
Cached Biology Technology:Florida Children's Hospital and Disney Unite to Create Magical Pediatric Hospital 2Florida Children's Hospital and Disney Unite to Create Magical Pediatric Hospital 3Florida Children's Hospital and Disney Unite to Create Magical Pediatric Hospital 4Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 2Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 4Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 5Indevus Announces Allergan as New Partner for SANCTURA Brand 2Indevus Announces Allergan as New Partner for SANCTURA Brand 3Indevus Announces Allergan as New Partner for SANCTURA Brand 4Indevus Announces Allergan as New Partner for SANCTURA Brand 5Indevus Announces Allergan as New Partner for SANCTURA Brand 6
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
(Date:11/6/2014)... a team of Florida State University biologists could lead ... to and survive environmental swings such as droughts or ... of the journal The Plant Cell , sheds ... proteins) is organized in a cell and how plants ... on and others are turned off. , "If you ...
(Date:11/6/2014)... - Insilico Medicine, Inc, a Baltimore-based bioinformatics company ... diseases announced a research collaboration with the international ... Inc (OTC: CSBR). , "There are many companies ... Champions Oncology,s TumorGraft technology is unique in a ... experimentally generating vast amounts of valuable data. Our ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... COLUMBIA, Mo. Asian-American youth are one of the ... Americans begin smoking later in life, they are more ... than other ethnic or racial groups, according to the ... of Missouri researcher is examining the unique differences in ...
... acclaimed scientist, explorer and conservationist, will receive the Academy ... today. He is the first Australian to receive the ... Australia,s leading thinkers and writers, Flannery has discovered more ... He has published more than 130 peer-reviewed scientific papers ...
... research has provided the first evidence that ,gender bending, chemicals ... oceans can have a significant impact on the ability of ... the four year study, led by the universities of Exeter ... these chemicals on ecosystem health and possibly on humans. ...
Cached Biology News:School attendance, refusal skills combat smoking risk in youth 2Scientist Tim Flannery is first Austrailian to receive Joseph Leidy Award 2Research proves 'gender-bending' chemicals affect reproduction 2
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
... from balances and scales with RS232 ports and ... If you can type the weight into the ... Simple to use parser extracts required data ... user information , Collect data at timed intervals ...
Peptide-affinity Purified Polyclonal Antibody to Prolactin Releasing Hormone Receptor (GPR10)...
Biology Products: